{"entity":{"id":"nct05438420","kind":"trial","name":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in cervical cancer, run by Qurient Co., Ltd., active and no longer recruiting.","summary":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05438420 by Qurient Co., Ltd., with 120 participants planned, started 2023-01-12 and due to reach its primary completion in 2027-12-30. Interventions recorded: Q702, Pembrolizumab. Conditions listed: Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05438420","url":"https://clinicaltrials.gov/study/NCT05438420"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05438420","phase":"1/2","setting":"A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors","sponsor":"Qurient Co., Ltd.","enrolled":120,"outcomes":[]},"route":"/trials/nct05438420/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}